Literature DB >> 18040738

Is the use of fullerene in photodynamic therapy effective for atherosclerosis?

Norihisa Nitta1, Ayumi Seko, Akinaga Sonoda, Shinichi Ohta, Toyohiko Tanaka, Masashi Takahashi, Kiyoshi Murata, Shizuki Takemura, Tsutomu Sakamoto, Yasuhiko Tabata.   

Abstract

The purpose of this study was to evaluate Fullerene as a therapeutic photosensitizer in the treatment of atherosclerosis. An atherosclerotic experimental rabbit model was prepared by causing intimal injury to bilateral external iliac arteries using balloon expansion. In four atherosclerotic rabbits and one normal rabbit, polyethylene glycol-modified Fullerene (Fullerene-PEG) was infused into the left external iliac artery and illuminated by light emitting diode (LED), while the right external iliac artery was only illuminated by LED. Two weeks later, the histological findings for each iliac artery were evaluated quantitatively and comparisons were made among atherosclerotic Fullerene+LED artery (n = 4), atherosclerotic light artery (n = 4), normal Fullerene+LED artery (n = 1), and normal light artery (n = 1). An additional two atherosclerotic rabbits were studied by fluorescence microscopy, after Fullerene-PEG-Cy5 complex infusion into the left external iliac artery, for evaluation of Fullerene-PEG incorporated within the atherosclerotic lesions. The degree of atherosclerosis in the atherosclerotic Fullerene+LED artery was significantly (p < 0.05) more severe than that in the atherosclerotic LED artery. No pathological change was observed in normal Fullerene+LED and LED arteries. In addition, strong accumulation of Fullerene-PEG-Cy5 complex within the plaque of the left iliac artery of the two rabbits was demonstrated, in contrast to no accumulation in the right iliac artery. We conclude that infusion of a high concentration of Fullerene-PEG followed by photo-illumination resulted not in a suppression of atherosclerosis but in a progression of atherosclerosis in experimental rabbit models. However, this intervention showed no adverse effects on the normal iliac artery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040738     DOI: 10.1007/s00270-007-9238-8

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  7 in total

1.  Photodynamic therapy with fullerenes in vivo: reality or a dream?

Authors:  Sulbha K Sharma; Long Y Chiang; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2011-12       Impact factor: 5.307

2.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

3.  Synthesis and characterization of highly photoresponsive fullerenyl dyads with a close chromophore antenna-C(60) contact and effective photodynamic potential.

Authors:  Long Y Chiang; Prashant A Padmawar; Joy E Rogers-Haley; Grace So; Taizoon Canteenwala; Sammaiah Thota; Loon-Seng Tan; Kenneth Pritzker; Ying-Ying Huang; Sulbha K Sharma; Divya Balachandran Kurup; Michael R Hamblin; Brian Wilson; Augustine Urbas
Journal:  J Mater Chem       Date:  2010-01-01

Review 4.  Functionalized fullerenes in photodynamic therapy.

Authors:  Ying-Ying Huang; Sulbha K Sharma; Rui Yin; Tanupriya Agrawal; Long Y Chiang; Michael R Hamblin
Journal:  J Biomed Nanotechnol       Date:  2014-09       Impact factor: 4.099

5.  Chemiexcited Photodynamic Therapy Integrated in Polymeric Nanoparticles Capable of MRI Against Atherosclerosis.

Authors:  Dan Mu; Xin Wang; Huiting Wang; Xuan Sun; Qing Dai; Pin Lv; Renyuan Liu; Yu Qi; Jun Xie; Biao Xu; Bing Zhang
Journal:  Int J Nanomedicine       Date:  2022-05-20

6.  Fullerenes as photosensitizers in photodynamic therapy: pros and cons.

Authors:  Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2018-07-25       Impact factor: 3.982

Review 7.  Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.

Authors:  Jun Chen; Xixi Zhang; Reid Millican; Jennifer Sherwood; Sean Martin; Hanjoong Jo; Young-Sup Yoon; Brigitta C Brott; Ho-Wook Jun
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 15.470

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.